Response to sapropterin hydrochloride (Kuvan®) in children with phenylketonuria (PKU): a clinical trial

Abstract

AbstractBackgroundPhenylketonuria (PKU) is one of the most common types of inborn error of metabolism. The mainstay of therapy for PKU has been dietary phenylalanine (Phe) restriction. Sapropterin dihydrochloride has been shown to be effective in reducing Phe levels in PKU patients.MethodsThis study was a clinical trial performed in the pediatric endocrine clinic of Imam Reza Hospital, Mashhad, Iran.ResultsAll children between 1 and 10 years of age with a diagnosis of PKU whose serum Phe levels were between 120 and 360 μmol/L, in Khorasan Razavi province in the north-east of Iran, were enrolled. Twenty-four patients were enrolled in the study.Intervention: A free diet for 72 h was allowed and then a 20-mg/kg/day dose of Kuvan®was administered. More than 30% reduction in blood Phe levels was described as responsive. Eight patients responded to the loading test and were eligible for the second stage of the study. In this stage, Phe powder in combination with Kuvan was provided. Patients’ serum Phe was measured weekly for 3 months. All eight patients showed Phe tolerance in 3 months, and their serum Phe levels remained within the range.ConclusionsTreatment with Kuvan can help reduce blood Phe levels in our pediatric PKU population and allows patients to follow a more liberal diet.